Top Page
Takeda Pharmaceutical Co
(OTC:4502)
Takeda Pharmaceutical Co (4502) vs. iShares MSCI Japan ETF (EWJ)
Takeda Pharmaceutical Co Business Overview & Revenue Model
Takeda Pharmaceutical Co Earnings Call Summary
Takeda Pharmaceutical Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.48T | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T |
| Gross Profit | 2.71T | 2.36T | 2.83T | 2.78T | 2.46T | 2.20T |
| EBITDA | 1.21T | 1.15T | 874.60B | 1.18T | 1.18T | 983.72B |
| Net Income | 136.92B | 107.93B | 144.07B | 317.02B | 230.06B | 376.00B |
Balance Sheet | ||||||
| Total Assets | 14.00T | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T |
| Cash, Cash Equivalents and Short-Term Investments | 419.18B | 385.11B | 457.80B | 553.70B | 875.00B | 1.00T |
| Total Debt | 4.51T | 4.52T | 4.84T | 4.38T | 4.35T | 4.64T |
| Total Liabilities | 7.14T | 7.31T | 7.83T | 7.60T | 7.49T | 7.74T |
| Stockholders Equity | 6.87T | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T |
Cash Flow | ||||||
| Free Cash Flow | 831.40B | 761.70B | 235.61B | 343.47B | 937.07B | 774.46B |
| Operating Cash Flow | 1.07T | 962.49B | 716.34B | 977.16B | 1.12T | 1.01T |
| Investing Cash Flow | -243.56B | -367.06B | -463.86B | -607.10B | -198.13B | 393.53B |
| Financing Cash Flow | -1.28T | -751.42B | -354.42B | -709.15B | -1.07T | -1.09T |
Takeda Pharmaceutical Co Technical Analysis
Takeda Pharmaceutical Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $6.99T | 50.56 | 1.99% | 4.45% | 1.52% | -8.68% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% | |
| ― | $3.64B | 29.97 | 10.94% | ― | ― | ― | |
| ― | $8.88B | 26.06 | 5.96% | 3.52% | ― | ― | |
| ― | $2.15B | 16.66 | 7.24% | 2.00% | ― | ― | |
| ― | $15.77B | 11.93 | 13.71% | 4.84% | ― | ― | |
| ― | $1.86B | 10.82 | 9.09% | 3.99% | ― | ― |
Takeda Pharmaceutical Co Corporate Events
Takeda Pharmaceutical Co announced that an abstract for their Phase 3 study of the drug oveporexton (TAK-861) for narcolepsy type 1 was inadvertently published by the World Sleep Congress. The abstract was quickly removed, and Takeda plans to present the positive results of their Phase 3 studies at the upcoming World Sleep 2025 congress. The studies met all primary and secondary endpoints, highlighting oveporexton’s potential to transform the standard of care for narcolepsy type 1. Takeda does not expect this incident to significantly impact its financial results.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4200.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Company reported its consolidated financial results for the three-month period ending June 30, 2025. The company experienced a decline in revenue by 8.4% compared to the previous year, but saw an increase in operating profit and net profit by 11.0% and 30.4% respectively. The company maintains its management guidance for the fiscal year ending March 31, 2026, with expectations of broadly flat growth in core revenue, core operating profit, and core EPS.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co announced positive results from two pivotal Phase 3 studies of oveporexton (TAK-861) in treating narcolepsy type 1. The studies met all primary and secondary endpoints, demonstrating statistically significant improvements across symptoms and reinforcing the potential of oveporexton to transform the standard of care. The drug was generally well-tolerated, and Takeda is advancing regulatory submissions to bring oveporexton to market quickly. This development marks a significant advancement in addressing the underlying cause of narcolepsy type 1 and positions Takeda for future growth in the orexin biology field.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co. has completed the disposal of treasury shares under its Long-Term Incentive Plan for employees outside Japan, with a slight reduction in the number of shares due to partial forfeiture of rights by some allottees. This change is expected to have an immaterial impact on the company’s full-year financials, indicating a stable operational outlook despite the adjustment.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co announced new assignments of directors following its 149th Annual Meeting of Shareholders. The board, comprised predominantly of external directors, underscores Takeda’s commitment to strong, independent governance. This governance model is crucial for aligning decisions with stakeholder interests and maintaining the company’s values. The new assignments include roles in the Nomination and Compensation Committees, further emphasizing the company’s focus on transparency and objectivity in its operations.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4200.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co announced the disposal of 17,355,770 treasury shares under its Long-Term Incentive Plan (LTIP) for employees outside Japan, valued at 75.25 billion yen. This initiative aims to align employee interests with shareholders, attract and retain talent, and balance risk and reward, potentially enhancing the company’s competitive positioning and operational efficiency.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co. announced its plan to withdraw a previous Shelf Registration Statement and file a new one in Japan to issue new shares or dispose of treasury shares. This move is aimed at supporting the company’s Long Term Incentive Plan (LTIP) for employees. The scheduled issue amount is up to JPY 220 billion, with an expected share dilution of around 1.1% for the fiscal year ending March 31, 2026. This strategic decision allows Takeda to manage its equity more flexibly and aligns with its ongoing efforts to incentivize its workforce.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda and Protagonist Therapeutics announced the full 32-week results of their Phase 3 VERIFY study on rusfertide, presented at the ASCO Annual Meeting. The study, which targeted patients with polycythemia vera, successfully met its primary and secondary endpoints, demonstrating significant reductions in phlebotomy and improved hematocrit control. Despite the positive clinical outcomes, the impact on Takeda’s financial results for FY2025 is expected to be minimal.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.